glp 1 receptor agonists and kidney protection Glucagon-like peptide-1 signaling modifies the extent of diabetic disease through dampening the receptor for advanced glycation end products–induced inflammation A Comprehensive Review of the
Description
How do you start a GLP-1 for weight loss
The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits
This product is not for human consumption, medical, therapeutic, or diagnostic use
After a few years of injectable dominance, oral formulations are emerging as a game-changer for adherence and ease of use thanks to their lack of cold-chain requirement, but also a game-changer for their ability to unlock the long-term maintenance opportunity [14]
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
